ClinicalTrials.gg
CompletedNCT06571448Updated Apr 24, 2026

Efficacy, Safety, and Tolerability of SR750 in Patients With Trigeminal Neuralgia

A Phase 2 interventional study of SR750 tablet and SR750 tablet in Trigeminal Neuralgia, sponsored by Shanghai SIMR Biotechnology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Shanghai SIMR Biotechnology Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Trigeminal Neuralgia with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Trigeminal Neuralgia · China.

Enrollment
6th of 13
138 · median 134
Started
2024
with 2 others
Phase 2
2 of 17
1 open now
Registered
14th of 17
by date
Lead sponsor
1 of 17
Shanghai SIMR Biotechnology Co., Ltd.

Among the 17 studies in Trigeminal Neuralgia with a site in China, this one is the 6th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2024, is one of 2 in phase 2, and was the 14th registered.

Trigeminal Neuralgia

140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.

Browse Trigeminal Neuralgia studies →

Open to participants now

6 of the 17 studies in Trigeminal Neuralgia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Trigeminal Neuralgia with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy,safety and tolerability of SR750 in patients with trigeminal neuralgia (TN). Patients will receive SR750 (study drug) or placebo for 6 weeks and keep a diary of daily pain. The study duration for each patient is up to 11 weeks.

Read the detailed description

This is a phase 2, randomized, double-blind study comparing SR750 with placebo in patients with trigeminal neuralgia. It consists of a screening period, a double-blind treatment period, and a post-treatment safety follow-up period. Baseline pain intensity and number of paroxysms will be taken in the run-in period of screening period and will be checked for eligibility. Around 162 eligible subjects will be recruited and randomized into three arms at 1:1:1 ratio to receive SR750 high dose twice a day (BID) , SR750 low dose BID or placebo BID for 6 weeks. Subjects, investigators, all clinical study site staffs, and the Sponsor will remain blinded to treatment assignment during the study. Subjects will be asked to record the number of paroxysms of pain, severity of daily average pain of paroxysms and severity of daily worst pain in e-diary over the last 24 hours every night before going to bed. After completion of double-blind period, subjects will continue to complete the safety follow-up.

03

Conditions studied

  • Trigeminal Neuralgia

Browse trials for

Keywords

  • Trigeminal Neuralgia
  • SR750
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of trigeminal neuralgia as per International Classification of Headache Disorders third version (ICHD-3) criteria
  • Subjects must have experienced ≥3 paroxysms per day with a daily average pain sore of ≥4 and ≤8 on PI-NRS during the five days prior to randomization.
  • Willing and able to undergo washout of prohibited medication as per protocol requirements and refrain from use of the prohibited medication throughout the study period.
  • Female subjects must be non-pregnant and non-lactating.

Key Exclusion Criteria:

  • Secondary trigeminal neuralgia
  • Painful trigeminal neuropathies
  • Other pains that cannot be clearly differentiated from the pain associated with TN or may interfere with the pain assessment
  • Subjects have previously undergone microvascular decompression (MVD), sensory rhizotomy of trigeminal nerve, radiofrequency ablation (RFA), percutaneous balloon compression (PBC), permanent lesion of trigeminal semilunar ganglion, botulinum toxin type A for the treatment of TN within 6 months prior to screening. Subjects with severe complication after therapeutic procedure would also be excluded.
  • Known history of (HIV) or active infection of virus (HBV), virus (HCV) or Treponema Pallidum
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    SR750 high dose

    Drug: SR750 tablet

  • Experimental
    SR750 low dose

    Drug: SR750 tablet

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSR750 tablet

    SR750 high dose BID orally for 6 weeks

  • DrugSR750 tablet

    SR750 low dose BID orally for 6 weeks

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Daily Average Pain Score (DAPS)

    Change from baseline to week 6 in the weekly average of the daily average pain score (DAPS) of paroxysms using pain intensity numerical rating scale (PI-NRS).The PI-NRS consists of an 11-point numeric scale ranging from 0 (no pain) to 10 (worst imaginable pain). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10.

    Time frame: up to week 6

Secondary outcomes

  1. Proportion of responders

    Proportion of subjects who meets one of the following criteria, * Patient Global Impression of Change (PGIC) response of "Much Improved" or "Very Much Improved" at Week 6. Subjects will select a value to represent their overall status since the start of the study on a 7-point scale of PGIC on which 1 corresponds to "very much improved", 2 corresponds to "much improved", 3 corresponds to "slightly improved" 4 corresponds to "no change", 5 corresponds to "slightly worse", 6 corresponds to "much worse", and 7 corresponds to "very much worse". * A reduction of ≥2 points from baseline in mean pain score at Week 6 * A reduction of ≥30% from baseline in mean pain score at Week 6 * A reduction of ≥50% from baseline in mean pain score at Week 6 * A reduction of ≥30% from baseline in mean number of paroxysms at Week 6 * A reduction of ≥50% from baseline in mean number of paroxysms at Week 6 * A reduction of ≥30% from baseline in mean worst pain score at Week 6

    Time frame: up to week 6

  2. Mean pain score by week

    Change from baseline in weekly mean pain score. The daily pain score will be measured by PI-NRS described as above.

    Time frame: up to week 6

  3. Mean worst pain score by week

    Change from baseline in mean worst pain score by week. The daily worst pain score will be measured by PI-NRS described as above.

    Time frame: up to week 6

  4. Mean number of paroxysms by week

    Change from baseline in mean number of paroxysms by week

    Time frame: up to week 6

  5. Mean continuous pain score by week

    Change from baseline in mean continuous pain score by week. The daily continuous pain score will be measured by PI-NRS described as above.

    Time frame: up to week 6

  6. Proportion of subjects with continuous pain at week 6

    Change of proportion from baseline

    Time frame: up to week 6

  7. Hospital Anxiety and Depression Scale (HADS)

    Change of HADS from baseline. The HADS is a self-administered questionnaire consisting of two subscales, one for anxiety (HADS-A Subscale) and the other for depression (HADS-D Subscale). Each subscale consists of 7 items, and subjects will rate each item as it applies to them 0 points = absence of anxiety or depression; 3 points = severe anxiety or depression. The HADS-A Subscale analyzes generalized anxiety states, including anxious feelings, restlessness, anxious thoughts, and panic attacks. The HADS-D Subscale focuses on states of loss of interest and reduced pleasure response (reduced enjoyment mood). Each subscale will receive a score from 0 to 21, with bigger number indicating more severe symptom.

    Time frame: up to week 6

  8. Use of rescue medication

    Including the first time to use rescue medication, total amount and proportion

    Time frame: up to week 7

Other outcomes

  1. Adverse events

    To collect the adverse events during the study

    Time frame: up to week 7

  2. Plasma concentration of SR750 and its metabolite

    To measure the plasma concentration of SR750 and its metabolite after dosing

    Time frame: up to day 43

07

Study locations

1 site
  • China-Japan Friendship Hospital
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Jan 2026, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2024
First posted
Aug 26, 2024
StartActual
Sep 16, 2024
Primary completionActual
Jan 26, 2026
CompletionActual
Feb 24, 2026
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06571448
Lead sponsor
Shanghai SIMR Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Aug 26, 2024
Start date
Sep 16, 2024
Primary completion
Jan 26, 2026
Completion
Feb 24, 2026
Last update
Apr 24, 2026

Study contacts

Bifa Fan, MD
principal investigator · China-Japan Friendship Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion